Jefferies upgraded Ionis Pharmaceuticals to Buy from Underperform with a price target of $75, up from $29, as the analyst assumed coverage of the stock. The firm, which is “mainly bullish” on Eplontersen in ATTR-CM and thinks the Phase 3 CARDIO-TTRansform data due in mid-2026 reads out positively, contends that at about $48 per share “there’s still upside” for Ionis. The firm estimates that the company’s de-risked base business has a net present value of about $35 per share and says Ionis has a diversified pipeline that offers optionality.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $53 from $50 at Stifel
- Ionis Pharmaceuticals announces FDA acceptance of olezarsen NDA
- Ionis Pharma expands donidalorsen licensing agreement in Asia Pacific
- Ionis Pharmaceuticals upgraded to Market Perform from Underperform at Bernstein
- JPMorgan biotech analysts hold an analyst/industry conference call